DrugPatentWatch Database Preview
Patent: 6,306,423
» See Plans and Pricing
Summary for Patent: 6,306,423
| Title: | Neurotoxin implant |
| Abstract: | A biocompatible implant for continuous in vivo release of a neurotoxin over a treatment period extending from one month to five years. The implant can be made of casting a solution of a polymer, such as an ethyl vinyl acetate copolymer and the neurotoxin. The neurotoxin can be a botulinum toxin. |
| Inventor(s): | Donovan; Stephen (Capistrano Beach, CA), Brady; Daniel G. (San Juan Capistrano, CA) |
| Assignee: | Allergan Sales, Inc. (Irvine, CA) |
| Application Number: | 09/587,250 |
| Patent Claims: | see list of patent claims |
Details for Patent 6,306,423
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Number | Approval Date | Patent No. | Assignee | Estimated Patent Expiration | Status | Orphan | Source |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Elan Pharm | MYOBLOC | botulinum toxin type b | VIAL | 103846 | 001 | 2000-12-08 | Start Trial | Allergan Sales, Inc. (Irvine, CA) | 2039-02-26 | RX | search | |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Number | >Approval Date | >Patent No. | >Assignee | >Estimated Patent Expiration | >Status | >Orphan | >Source |
International Patent Family for US Patent 6,306,423
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| World Intellectual Property Organization (WIPO) | 0193827 | Start Trial |
| World Intellectual Property Organization (WIPO) | 0193890 | Start Trial |
| United States of America | 2002028216 | Start Trial |
| United States of America | 2002028244 | Start Trial |
| United States of America | 2002098237 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
